{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:30Z","timestamp":1760144010809,"version":"build-2065373602"},"reference-count":92,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed\/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed\/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed\/refractory PTCL.<\/jats:p>","DOI":"10.3390\/jpm12060964","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2517-9943","authenticated-orcid":false,"given":"Zachary","family":"Braunstein","sequence":"first","affiliation":[{"name":"Wexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Wexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[{"name":"James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polina","family":"Shindiapina","sequence":"additional","affiliation":[{"name":"James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-2410","authenticated-orcid":false,"given":"John C.","family":"Reneau","sequence":"additional","affiliation":[{"name":"James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Brammer","sequence":"additional","affiliation":[{"name":"James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11899-020-00590-5","article-title":"Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma","volume":"15","author":"Rogers","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","article-title":"Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity","volume":"87","author":"Elstrom","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_13","unstructured":"Network NCC (2020). T-Cell Lymphomas. NCCN Clinical Practice Guidelines, National Comprehensive Cancer Network."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-013-1738-9","article-title":"DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: A retrospective evaluation of parallel patient cohorts of one center","volume":"92","author":"Mikesch","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin. Epigenet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17474086.2019.1583102","article-title":"New directions in treating peripheral T-cell lymphomas (PTCL): Leveraging epigenetic modifiers alone and in combination","volume":"12","author":"Ma","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-021-00200-x","article-title":"Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas","volume":"10","author":"Ye","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref_27","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mrakovcic, M., Kleinheinz, J., and Fr\u00f6hlich, L.F. (2019). p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102415"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/onc.2012.81","article-title":"Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8","volume":"32","author":"Yan","year":"2013","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"Horwitz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20302","DOI":"10.1038\/s41598-019-56891-0","article-title":"Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: A multicenter retrospective analysis","volume":"9","author":"Hong","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428194.2020.1765232","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: A pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1182\/blood-2018-99-119489","article-title":"Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","article-title":"Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma","volume":"30","author":"Dong","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: The Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ejh.13568","article-title":"Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma","volume":"106","author":"Coppo","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","article-title":"NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021","volume":"18","author":"Horwitz","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","article-title":"The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas","volume":"14","author":"Karube","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-136917","article-title":"Brentuximab Vedotin As Single Agent in the Treatment of Relapsed\/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi","volume":"136","author":"Stefoni","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2017-12-820258","article-title":"Dual PI3K blockade: PTCL\u2019s Achilles heel?","volume":"131","author":"Brammer","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2021-146657","article-title":"Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (ds-3201B) in Patients with Relapsed or Refractory Adult T-Cell Leukemia\/Lymphoma","volume":"138","author":"Yoshimitsu","year":"2021","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ishitsuka, K., Izutsu, K., Maruyama, D., Makita, S., Jacobsen, E.D., Horwitz, S., Kusumoto, S., Allen, P., Porcu, P., and Imaizumi, Y. (2021). First-in-human study of the ezh1 and ezh2 dual inhibitor valemetostat tosylate (ds-3201b) in patients with relapsed or refractory non-hodgkin lymphomas. Hematol. Oncol., 39.","DOI":"10.1002\/hon.14_2879"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2021-144676","article-title":"A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL), Including R\/R Afult T-cell Leukemia\/Lymphoma (ATL)-Valentine-PTCL01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-136465","article-title":"A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed\/refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)","volume":"136","author":"Chavez","year":"2021","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.reprotox.2017.08.018","article-title":"Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring","volume":"74","author":"Nicholson","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-137782","article-title":"Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma","volume":"136","author":"Khodadoust","year":"2020","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014238","article-title":"JAK\/STAT: A pathway through the maze of PTCL?","volume":"138","year":"2021","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood-2021-152603","article-title":"Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed\/Refractory (R\/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b\/2 VT3996-201 Study","volume":"138","author":"Haverkos","year":"2021","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2021-150953","article-title":"Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed\/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study","volume":"138","author":"Bouabdallah","year":"2021","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2021-145851","article-title":"Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed\/Refractory T-Cell Lymphoma: Final Results from a Phase I\/II Open Label Multi-Center Study","volume":"138","author":"Iyer","year":"2021","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1080\/10428194.2019.1622100","article-title":"A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)","volume":"60","author":"Park","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study","volume":"134","author":"Falchi","year":"2019","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","article-title":"Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 \u201cDon\u2019t Eat Me\u201d Signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eaaf2968","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRP\u03b1 requires Fc-Fc\u03b3R interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"a002287","DOI":"10.1101\/cshperspect.a002287","article-title":"T-cell signaling regulated by the Tec family kinase, Itk","volume":"2","author":"Andreotti","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0b013e3182991415","article-title":"ITK\/SYK translocation in angioimmunoblastic T-cell lymphoma","volume":"37","author":"Attygalle","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/PAS.0000000000000309","article-title":"Intracellular TCR-signaling pathway: Novel markers for lymphoma diagnosis and potential therapeutic targets","volume":"38","author":"Agostinelli","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma","volume":"207","author":"Pechloff","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1038\/s41598-018-32634-5","article-title":"Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma","volume":"8","author":"Mamand","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/PAS.0000000000000188","article-title":"Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T\/NK-cell lymphomas. A North American PTCL study group project","volume":"38","author":"Hsi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000516588","article-title":"Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas","volume":"145","author":"Zhao","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"797028","DOI":"10.3389\/fonc.2021.797028","article-title":"Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma","volume":"11","author":"Kim","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J. Virol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:49Z","timestamp":1760138929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":92,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jpm12060964"],"URL":"https:\/\/doi.org\/10.3390\/jpm12060964","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}